Hisamori, Shigeo
Mukohyama, Junko
Koul, Sanjay
Hayashi, Takanori
Rothenberg, Michael Evan
Maeda, Masao
Isobe, Taichi
Valencia Salazar, Luis Enrique http://orcid.org/0000-0002-5499-1394
Qian, Xin
Johnston, Darius Michael
Qian, Dalong
Lao, Kaiqin
Asai, Naoya
Kakeji, Yoshihiro
Gennarino, Vincenzo Alessandro
Sahoo, Debashis
Dalerba, Piero
Shimono, Yohei http://orcid.org/0000-0002-6256-4704
Funding for this research was provided by:
Japan Society for the Promotion of Science (15K14381, 18K07231, 19K09106, 21H02769, 17K16555)
Uehara Memorial Foundation
Cell Science Research Foundation
New York State Stem Cell Science (DOH01-C30291GG-3450000)
Princess Takamatsu Cancer Research Fund
Fujita Health University
Kanazawa University
Japan association for development of community medicine
BD Biosciences
Damon Runyon Cancer Research Foundation (DRR-44-16)
Columbia University
National Institute of Diabetes and Digestive and Kidney Diseases (K08-DK097181)
National Cancer Institute (R00-CA151673)
National Institute of General Medical Sciences (R01-GM138385)
National Institute of Dental and Craniofacial Research (R01-DE028961)
Promotion and Mutual Aid Corporation for Private Schools of Japan
Article History
Received: 13 May 2021
Accepted: 10 February 2022
First Online: 4 March 2022
Declarations
:
: Yohei Shimono is co-inventor on a patent application owned by <i>Stanford</i><i>University</i> (US-20110021607), describing the use of miRNAs, including <i>miR-200c</i>, as biomarkers for the identification and therapeutic targeting of cancer stem cells. Yohei Shimono holds a financial relationship with a pharmaceutical company that might be considered relevant to this study: <i>Quanticel Pharmaceuticals</i>, now a fully owned subsidiary of <i>Celgene</i> and <i>Bristol Myers Squibb</i> (patent royalties, stock ownership). Piero Dalerba is co-inventor on patents and patent applications owned by the <i>University</i><i>of</i><i>Michigan</i> (US-7723112, US-20140030786) and <i>Stanford</i><i>University</i> (US-9329170, US-09850483) and describing the use of EpCAM, CD44 and CD66a/CEACAM1 as bio-markers for the identification and differential purification of different subsets of colon epithelial cells. Piero Dalerba holds financial relationships with pharmaceutical and biotechnological companies that might be considered relevant to this study, including relationships with: <i>Oncomed Pharmaceuticals</i>, now a fully owned subsidiary of the <i>Mereo BioPharma Group</i> (patent royalties), <i>Quanticel Pharmaceuticals</i>, now a fully owned subsidiary of <i>Celgene</i> and <i>Bristol Myers Squibb</i> (patent royalties, stock ownership), <i>Forty Seven Inc.</i>, now a fully owned subsidiary of <i>Gilead Sciences Inc.</i> (patent royalties, stock ownership), <i>Amgen</i> (stock ownership), <i>Alexion Pharmaceuticals Inc.</i> (employment of an immediate family member, stock ownership), <i>AstraZeneca plc</i> (stock ownership), <i>Eli Lilly and Company</i> (stock ownership), <i>Merck & Co Inc.</i> (stock ownership) and <i>Pfizer Inc.</i> (stock ownership). Piero Dalerba received a grant from <i>BD Biosciences</i>. Piero Dalerba received an honorarium from the <i>Samsung Medical Center</i> to give a scientific lecture. Michael E. Rothenberg is co-inventor on a patent application owned by <i>Stanford</i><i>University</i> (US-20130225435), describing the use of CEACAM1/CD66a as bio-marker for the identification and differential purification of different subsets of colon epithelial cells, and is currently an employee of <i>Genentech</i>, now a fully owned subsidiary of <i>Roche Holding AG</i>. Kaiqin Lao was an employee of <i>Thermo Fisher Scientific</i>, which commercializes some of the reagents used in this study for the analysis of miRNA expression levels, and currently serves as the <i>chief</i><i>executive</i><i>officer</i> (CEO) of <i>X Gen US</i>. Shigeo Hisamori, Junko Mukohyama, Taichi Isobe, Luis E. Valencia Salazar, Xin Qian, Darius M. Johnston, Dalong Qian, Yoshihiro Kakeji, Vincenzo A. Gennarino and Debashis Sahoo disclose no conflicts of interest considered relevant to this study.